Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122767404 | 12276740 | 4 | F | 20160329 | 20160708 | 20160418 | 20160708 | EXP | US-PFIZER INC-2016188625 | PFIZER | 7.00 | YR | M | Y | 0.00000 | 20160708 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122767404 | 12276740 | 1 | PS | GABAPENTIN. | GABAPENTIN | 1 | Oral | 250MG/5ML, 2CC LIQUID ONCE | N | 21129 | 100 | MG | ORAL SOLUTION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 122767404 | 12276740 | 1 | Neuralgia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 122767404 | 12276740 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 122767404 | 12276740 | Encephalitis autoimmune | |
| 122767404 | 12276740 | Product use issue | |
| 122767404 | 12276740 | Psychotic disorder | |
| 122767404 | 12276740 | Selective mutism |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 122767404 | 12276740 | 1 | 20160329 | 20160329 | 0 |